These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16013669)

  • 1. Advances on biological markers in early diagnosis of Alzheimer disease.
    Padovani A; Borroni B; Di Luca M
    Adv Clin Chem; 2005; 39():107-29. PubMed ID: 16013669
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers for the early diagnosis of Alzheimer's disease.
    de Leon MJ; Klunk W
    Lancet Neurol; 2006 Mar; 5(3):198-9. PubMed ID: 16488371
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
    Dean RA; Shaw LM
    Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
    Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
    [No Abstract]   [Full Text] [Related]  

  • 5. Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker.
    Holtzman DM
    JAMA; 2010 Nov; 304(17):1887. PubMed ID: 21045090
    [No Abstract]   [Full Text] [Related]  

  • 6. Will CSF analysis become routine in people with memory complaints?
    Gauthier S
    Lancet Neurol; 2009 Jul; 8(7):595-6. PubMed ID: 19523878
    [No Abstract]   [Full Text] [Related]  

  • 7. [Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia].
    Uspenskaia OV; Iakhno NN; Belushkina NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(8):36-40. PubMed ID: 20823828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
    Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Alzheimer's indicator?
    Johns Hopkins Med Lett Health After 50; 2014 Jan; 25(13):6. PubMed ID: 24809125
    [No Abstract]   [Full Text] [Related]  

  • 12. Sharpen that needle.
    Herskovits AZ; Growdon JH
    Arch Neurol; 2010 Aug; 67(8):918-20. PubMed ID: 20697041
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
    Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ
    Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease.
    Rabinovici GD; Roberson ED
    Ann Neurol; 2010 Mar; 67(3):283-5. PubMed ID: 20373338
    [No Abstract]   [Full Text] [Related]  

  • 15. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
    Frisoni GB; Padovani A; Wahlund LO
    Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M; Andreasen N; Blennow K
    Clin Chim Acta; 2003 Jun; 332(1-2):1-10. PubMed ID: 12763273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in subjects with amnestic mild cognitive impairment.
    Maruyama M; Arai H; Ootsuki M; Matsui T; Sasaki H; Yamazaki T; Kaneta T; Okamura T
    J Am Geriatr Soc; 2003 Nov; 51(11):1671-2. PubMed ID: 14687403
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comments on the article by K. Buch et al. Tau protein: a potential biological marker for early detection of Alzheimer disease. Nervenarzt (1998) 69:379-385].
    Otto M; Wiltfang J; Poser S; Kornhuber J
    Nervenarzt; 1999 Jul; 70(7):668-70. PubMed ID: 10434268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.